The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
Quiz|Articles|August 23, 2026
Dermatology Times Spot Test: August 23, 2026
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- A weekly question-based feature is positioned as an ongoing self-assessment tool for clinicians tracking dermatology essentials and emerging science.
- This week’s quiz content targets vitiligo, steering attention to the latest news and developments relevant to clinical conversations.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on the latest news in
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
In the phase 1b trial, how did FB102 perform compared with placebo on mean FVASI improvement at week 24 in the efficacy-evaluable population?
What type of drug is LNK01004?
What did both TRANQUILLO and TRANQUILLO 2 trials of ritlecitinib demonstrate?
Advertisement
Related to this article
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Advertisement
Advertisement
Trending on Dermatology Times
1
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Tolerability and Response Criteria Guide Hedgehog Inhibitor Choice in Advanced BCC
4
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
5